DexTech Medical AB (XSAT:DEX) Cyclically Adjusted Revenue per Share: kr0.00 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSAT:DEX DexTech Medical AB XSAT:DEX
19 GF Score
Price kr10.35
! 3 Warning Signs
View Full Analysis

What is DexTech Medical AB Cyclically Adjusted Revenue per Share?

DexTech Medical AB XSAT:DEX 19 Cyclically Adjusted Revenue per Share is kr0.00 as of Mar. 2026. GuruFocus rates XSAT:DEX with a GF Score™ of 19/100. The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

DexTech Medical AB's adjusted revenue per share for the three months ended in Mar. 2026 was kr0.000. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is kr0.00 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-18), DexTech Medical AB's current stock price is kr10.35. DexTech Medical AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was kr0.00. DexTech Medical AB's Cyclically Adjusted PS Ratio of today is .


DexTech Medical AB  (XSAT:DEX) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


DexTech Medical AB Cyclically Adjusted Revenue per Share Related Terms


DexTech Medical AB Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for DexTech Medical AB's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DexTech Medical AB Cyclically Adjusted Revenue per Share Chart

DexTech Medical AB Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

DexTech Medical AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

XSAT:DEX vs VRTX, REGN, ALNY: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, DexTech Medical AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DexTech Medical AB Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DexTech Medical AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where DexTech Medical AB's Cyclically Adjusted PS Ratio falls into.


XSAT:DEX
19GF Score
DexTech Medical AB XSAT:DEX
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DexTech Medical AB Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, DexTech Medical AB's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0/133.5600*133.5600
=0.000

Current CPI (Mar. 2026) = 133.5600.

DexTech Medical AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.000 101.019 0.000
201609 0.000 101.138 0.000
201612 0.000 102.022 0.000
201703 0.000 102.022 0.000
201706 0.000 102.752 0.000
201709 0.000 103.279 0.000
201712 0.000 103.793 0.000
201803 0.000 103.962 0.000
201806 0.000 104.875 0.000
201809 0.000 105.679 0.000
201812 0.000 105.912 0.000
201903 0.000 105.886 0.000
201906 0.000 106.742 0.000
201909 0.000 107.214 0.000
201912 0.000 107.766 0.000
202003 0.000 106.563 0.000
202006 0.000 107.498 0.000
202009 0.000 107.635 0.000
202012 0.000 108.296 0.000
202103 0.000 108.360 0.000
202106 0.000 108.928 0.000
202109 0.000 110.338 0.000
202112 0.000 112.486 0.000
202203 0.000 114.825 0.000
202206 0.000 118.384 0.000
202209 0.000 122.296 0.000
202212 0.000 126.365 0.000
202303 0.000 127.042 0.000
202306 0.000 129.407 0.000
202309 0.000 130.224 0.000
202312 0.000 131.912 0.000
202403 0.000 132.205 0.000
202406 0.000 132.716 0.000
202409 0.000 132.304 0.000
202412 0.000 132.987 0.000
202503 0.000 132.825 0.000
202506 0.000 133.699 0.000
202509 0.000 133.480 0.000
202512 0.000 133.390 0.000
202603 0.000 133.560 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of kr0.00 mean?
DexTech Medical AB (XSAT:DEX) has a Cyclically Adjusted Revenue per Share of kr0.00 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on DexTech Medical AB and its competitors.
Is DexTech Medical AB's Cyclically Adjusted Revenue per Share too high?
DexTech Medical AB's current Cyclically Adjusted Revenue per Share is kr0.00. Overall, DexTech Medical AB has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does DexTech Medical AB's Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
DexTech Medical AB's Cyclically Adjusted Revenue per Share of kr0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on DexTech Medical AB and its competitors. DexTech Medical AB's current Cyclically Adjusted Revenue per Share is kr0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DexTech Medical AB stock overvalued right now?
DexTech Medical AB (XSAT:DEX) has a current Cyclically Adjusted Revenue per Share of kr0.00. The current Cyclically Adjusted Revenue per Share is kr0.00. DexTech Medical AB's overall GF Score™ is 19/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For DexTech Medical AB (XSAT:DEX), the current Cyclically Adjusted Revenue per Share is kr0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

DexTech Medical AB Business Description

Address Dag Hammarskjolds Vag 34A, Uppsala, SWE, 752 37
DexTech Medical AB is a Swedish research company specializing in drug development for urological oncology, with a prominent focus on prostate cancer. The company develops drug candidates using a proprietary carbohydrate platform, advancing treatments aimed at castration-resistant prostate cancer and related conditions. Its operations center on research, development, and licensing of these drug candidates. It has four drug candidates: OsteoDex, SomaDex, PSMA-binding conjugates, and GuaDex.
19GF Score

Get the complete analysis for XSAT:DEX

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr10.35
Price